• PP 3: Identity and Evidence Boundaries

  2026-10-19

  PP 3 is identified by APExBIO as 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine and a negative control for the Src kinase inhibitor PP 2. The available evidence supports its catalog identity and intended research role, but not an independently established mechanism, selectivity profile, or cellular outcome.

• Cy3 Maleimide: Mechanism and Evidence Limits

  2026-10-19

  APExBIO describes Cy3 maleimide (non-sulfonated), SKU A8138, as a maleimide-functionalized Cy3 fluorophore intended to form covalent attachments with thiol-containing biomolecules. The supplied evidence supports a product-level account of its reaction principle and reported optical properties, but does not establish performance, selectivity in complex samples, cellular uptake, or biological function through an identity-matched research study.

• EZ Cap™ CBEmax mRNA (m1Ψ): Evidence Scope

  2026-10-18

  APExBIO identifies R1044 as EZ Cap™ CBEmax mRNA (m1Ψ), a research-use cytosine base-editor mRNA. The available product information supports catalog identity and a category-level interpretation of intended cytosine base-editing measurements, but it does not establish molecular architecture, editing activity, fidelity, kinetics, delivery behavior, model applicability, or safety. No identity-matched research study, outcome statistics, or direct comparator data are available in the supplied evidence.

• Sulfo-Cy3 Azide: Identity, Mechanism and Evidence

  2026-10-17

  Sulfo-Cy3 azide (A8127) is described by APExBIO as a sulfonated, water-soluble Cy3 fluorescent bioconjugation reagent for azide–alkyne labeling. The documentation supports its intended chemical role, spectral identity and catalog-level formulation claims, but no identity-matched research paper or direct comparator is available to establish labeling efficiency, brightness, photostability or biological performance.

• EX 527: Identity, Mechanism, and Evidence Limits

  2026-10-16

  A source-attributed overview of EX 527 (SEN0014196) as a reported selective SIRT1 catalytic-activity inhibitor, emphasizing assay context, p53-acetylation readouts, and the limits created by the absence of an identity-matched primary publication.

• ELISA Stop Solution K4649: Evidence and Scope

  2026-10-16

  APExBIO lists K4649 as ELISA Stop Solution, but the available product information provides no formulation, chemical identity, performance data, or identity-matched research study. The product name supports only a limited assay-context interpretation: a reagent intended to terminate or stabilize a signal-generating stage of an ELISA. Any more specific claim about mechanism, compatibility, endpoint behavior, or assay performance would exceed the documented evidence.

• ML 348: What the Available Evidence Supports

  2026-10-15

  The APExBIO catalog identifies ML 348 as product SKU B4933, but the available product information does not document a chemical structure, biological target, mechanism, assay readout, or identity-matched research evidence. The scientifically defensible scope is therefore limited to catalog identity and explicit evidence boundaries.

• TMB Substrate for ELISA: What Is Documented

  2026-10-15

  APExBIO lists K1131 as a TMB substrate solution for ELISA, but no identity-matched research paper or product-specific performance data are available in the cited evidence. The documented scientific scope is therefore limited to the reagent’s named role as a chromogenic readout component and to the general distinction between upstream recognition and downstream enzymatic signal generation.

• AS 602801: What the Record Supports

  2026-10-14

  The available APExBIO catalog record identifies AS 602801 as SKU A3189 but supplies no description, mechanism, measurement principle, or identity-matched research evidence. The product listing therefore supports only a limited provenance statement and cannot substantiate biological activity, target engagement, assay performance, selectivity, or study outcomes.

• AP-2α, MGMT and Temozolomide Resistance

  2026-10-14

  A preclinical study links reduced AP-2α expression to elevated MGMT and temozolomide resistance in recurrent glioma models. Its findings support a transcriptional mechanism of resistance, but remain limited by the cell and mouse models and by the absence of clinical validation.

• AG-126 and the Limits of Cross-Model Inference

  2026-10-13

  AG-126 (Tyrphostin AG-126) is described by APExBIO as an ERK1/2 phosphorylation inhibitor, while a separate Advanced Science study links Neuroligin 1 loss in striatal D2-MSNs to repetitive behaviors through PKC-associated neuronal hyperactivation. The supplied evidence does not establish that AG-126 affects this autism-related mouse model or repetitive behavior.

• Chlorpromazine HCl: Evidence and Boundaries

  2026-10-13

  Chlorpromazine HCl is a phenothiazine dopamine receptor antagonist with established relevance to neuropharmacology studies and psychotic disorder research. The supplied 2024 study provides evidence that alternating-current electrical stimulation can increase magnetic nanoparticle uptake in several cancer-cell models, but it does not test chlorpromazine HCl. Any connection between the drug’s pharmacology and nanoparticle endocytosis therefore remains a research question rather than a demonstrated application.

• What the Wheat GRO-seq Study Shows

  2026-10-12

  The cited STAR Protocols paper presents a conceptual refinement of GRO-seq for studying transcriptional activity in complex wheat genomes. Its central reported result is a 20-fold increase in the proportion of valid data, although the supplied evidence does not establish that Aprotinin or other protease inhibitors contributed to this outcome.

• Ranolazine and HBV: What the Evidence Shows

  2026-10-12

  The supplied evidence does not provide a head-to-head comparison between Ranolazine and hepatitis B virus (HBV) mechanisms. The cited 2025 study supports a model in which HBsAg alters TBK1-linked interferon and autophagy signaling, while APExBIO’s product description frames Ranolazine as an anti-ischemic agent; no supplied evidence connects these pharmacological and virological contexts.

• PRKX, PD-L1 and Immune Heterogeneity in Gastric Cancer

  2026-10-11

  Wang et al. investigate how PRKX may define an immunosuppressive gastric-cancer subtype by stabilizing PD-L1, while also examining its potential association with response to anti-PD-1 therapy. The findings support a mechanistic model linking PRKX, PD-L1 persistence and CD8+ T-cell exhaustion, but the supplied evidence remains primarily preclinical and observational, with important limits on clinical applicability.

8645 records 1/577 page Next 12345 下5页 Last page